H.C. Wainwright analyst Debjit Chattopadhyay believes the "high preliminary bar set" by Sarepta Therapeutics, coupled with the likely initiation of its pivotal program by the end of 2018, and potential SRP-9001 commercialization during 2021, "adds to the hurdles" faced by peers. As such, the analyst would not be surprised if one or more of Sarepta's peers "dial down plans, if their data points an insurmountable chasm." The "near-term distortions" in Sarepta shares are creating long-term opportunities, Chattopadhyay tells investors in a research note. He sees Sarepta as attractive to own at current levels and keeps a Buy rating on the shares with a $267 price target.